Sage Therapeutics’ (SAGE) “Neutral” Rating Reiterated at HC Wainwright

Sage Therapeutics (NASDAQ:SAGE)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $12.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $14.00. HC Wainwright’s price objective would indicate a potential upside of 66.90% from the company’s previous close.

SAGE has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday, November 20th. TD Cowen cut their price target on shares of Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating on the stock in a research note on Thursday, November 21st. Truist Financial cut their target price on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating on the stock in a research note on Wednesday, October 30th. StockNews.com downgraded shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Finally, Oppenheimer cut their target price on shares of Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Wednesday, October 30th. Three investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Sage Therapeutics presently has an average rating of “Hold” and an average target price of $10.41.

Sage Therapeutics Stock Down 1.0 %

NASDAQ:SAGE opened at $7.19 on Wednesday. The company has a market cap of $439.81 million, a P/E ratio of -1.29 and a beta of 0.94. Sage Therapeutics has a fifty-two week low of $4.62 and a fifty-two week high of $27.39. The firm’s 50 day moving average is $6.28 and its two-hundred day moving average is $6.96.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. Research analysts forecast that Sage Therapeutics will post -6.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sage Therapeutics

Large investors have recently added to or reduced their stakes in the company. US Bancorp DE grew its holdings in Sage Therapeutics by 22.3% during the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 2,268 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in Sage Therapeutics by 21.6% during the 4th quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company’s stock worth $75,000 after acquiring an additional 2,446 shares in the last quarter. Picton Mahoney Asset Management grew its holdings in Sage Therapeutics by 126.0% during the 4th quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 3,581 shares in the last quarter. Geode Capital Management LLC grew its holdings in Sage Therapeutics by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock worth $8,975,000 after acquiring an additional 3,757 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Sage Therapeutics by 66.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock worth $85,000 after acquiring an additional 4,672 shares in the last quarter. 99.22% of the stock is owned by institutional investors and hedge funds.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.